Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Suspended 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1Breast 1

Conditions

Lymphoma, Non-Hodgkin 7Lymphoma, Large B-Cell, Diffuse 6Recurrence 5Lymphoma, Follicular 4Glioma 4Brain Neoplasms 4Rhabdoid Tumor 3Pinealoma 3Neuroectodermal Tumors, Primitive 3Neoplasms, Germ Cell and Embryonal 3Multiple Myeloma 3Medulloblastoma 3Lymphoma, Mantle-Cell 3Lymphoma, B-Cell 3Leukemia, Lymphocytic, Chronic, B-Cell 3Ependymoma 3Choroid Plexus Carcinoma 3Central Nervous System Neoplasms 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Neoplasms 2Neoplasm Metastasis 2Lymphoma, B-Cell, Marginal Zone 2Gliosarcoma 2Glioblastoma 2Colorectal Neoplasms 2Burkitt Lymphoma 2Uterine Cervical Neoplasms 1Stomach Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1

Interventions

Oxaliplatin 290Capecitabine 206Fluorouracil 181Cisplatin 168Docetaxel 138S 1 (combination) 132Paclitaxel 121Leucovorin 116Irinotecan 106pembrolizumab 103Trastuzumab 71apatinib 56Nivolumab 56sintilimab 45Drug Therapy 43Surgical Procedures, Operative 37Radiotherapy 37Bevacizumab 37Ramucirumab 34titanium silicide 31Hyperthermic Intraperitoneal Chemotherapy 30Epirubicin 30Carboplatin 30tislelizumab 28Cyclophosphamide 27XELOX 24Tegafur 23Folfox protocol 22Albumin-Bound Paclitaxel 22camrelizumab 21

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Stomach Neoplasms × Automobiles × Clear all
NCT04650451 2023-04-20

Safety and Activity Study of HER2-Targeted Dual Switch CAR-T Cells (BPX-603) in Subjects With HER2-Positive Solid Tumors

Bellicum Pharmaceuticals

Phase 1 Suspended
220 enrolled
BreastGastrointestinal

Breast Neoplasms, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡